The PI3K/mTOR inhibitor PKI-587 (gedatolisib) displayed an inhibitory effect on T-ALL cells and efficacy in T-ALL patients with poor prognosis. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.